Key Developments: Hologic Inc (HOLX.OQ)

HOLX.OQ on NASDAQ Stock Exchange Global Select Market

22.86USD
1 Aug 2013
Price Change (% chg)

$0.16 (+0.70%)
Prev Close
$22.70
Open
$22.88
Day's High
$23.24
Day's Low
$22.72
Volume
984,447
Avg. Vol
895,663
52-wk High
$23.96
52-wk Low
$18.46

Search Stocks

Latest Key Developments (Source: Significant Developments)

Hologic Inc Appoints Jack W. Cumming President And Chief Executive Officer
Thursday, 18 Jul 2013 04:01pm EDT 

Hologic Inc announced Jack W. Cumming has been named President and Chief Executive Officer, effective immediately. Mr. Cumming joined Hologic in 2001 and served as Chief Executive Officer from 2001 to 2009.  Full Article

Hologic Inc Reaffirms Q3 2013 Guidance
Thursday, 18 Jul 2013 04:01pm EDT 

Hologic Inc announced that for the third quarter of 2013, it expects revenues of approximately $626 million and non-GAAP adjusted earnings per share of $0.38. These preliminary results are in-line with the guidance previously provided on May 6, 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $626 million for the third quarter of 2013.  Full Article

Hologic Inc Reaffirms FY 2013 Guidance-Conference Call
Wednesday, 12 Jun 2013 01:40pm EDT 

Hologic Inc announced that it has revised fiscal 2013 revenue guidance a bit and expects to be between $2.53 billion to $2.55 billion and revised EPS guidance to be between $1.54 to $1.56. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $2.54 billion and EPS of $1.54 for fiscal 2013.  Full Article

Quest Diagnostics Inc And Hologic Inc Form Strategic Alliance To Improve Women's Health
Thursday, 6 Jun 2013 01:05pm EDT 

Quest Diagnostics Inc and Hologic Inc. (Hologic) announced that they have entered into a strategic alliance to more broadly offer testing based on Hologic's APTIMA family of products, as well as to co-develop and promote advanced diagnostic solutions to improve women's health. Under a non-exclusive agreement with an initial term of five years, the companies will focus primarily on clinical areas critical to the health of women. Quest Diagnostics will transition to a broader offering of services based on Hologic's APTIMA family of products, which includes FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas vaginalis. In addition, Quest Diagnostics will continue to utilize Hologic's leading line of ThinPrep liquid-based cytology products.  Full Article

Hologic Inc Receives FDA Approval For New Low-dose 3D Mammography (Breast Tomosynthesis) Solution For Breast Cancer Screening
Tuesday, 21 May 2013 08:15am EDT 

Hologic Inc announced that the U.S. Food and Drug Administration (FDA) approved the use of Hologic's new C-View 2D imaging software. C-View 2D images may be used in place of the conventional 2D exposure previously required as part of a Hologic 3D mammography (breast tomosynthesis) screening exam.  Full Article

Hologic Inc Updates FY 2013 Guidance To A Range In Line With Analysts' Estimates-Conference Call
Friday, 17 May 2013 11:40am EDT 

Hologic Inc announced that it has revised fiscal 2013 revenue guidance a bit and expects to be between $2.53 billion to $2.55 billion and revised EPS guidance to be between $1.54 to $1.56. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $2.54 billion and EPS of $1.54 for fiscal 2013.  Full Article

Hologic Inc Issues Q3 2013 Guidance Below Analysts' Estimates; Lowers FY 2013 Guidance
Monday, 6 May 2013 04:01pm EDT 

Hologic Inc announced that for the third quarter of 2013, it expects revenues of $625 million to $630 million and non--GAAP adjusted EPS of $0.36 to $0.37. For fiscal 2013, the Company is updating its expectation for non--GAAP adjusted revenues of $2.53 billion to $2.55 billion (from its previous expectation of $2.61 billion to $2.64 billion). The updated fiscal 2013 revenue guidance represents an increase of 26% to 27% over fiscal 2012 non--GAAP adjusted revenues of $2.01 billion. This increase is expected to be driven primarily by the Gen--Probe acquisition and, to a lesser extent, revenue increases in the Breast Health, GYN Surgical and legacy Diagnostics segments, partially offset by a reduction in Adiana system revenues ($11.1 million in year ended September 29, 2012). The Company now expects non--GAAP adjusted EPS of $1.54 to $1.56. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $655 million and EPS of $0.41 for the third quarter of 2013; revenues of $2.63 billion and EPS of $1.58 for fiscal 2013.  Full Article

Hologic Inc Completes Sale of LIFECODES to Immucor
Friday, 22 Mar 2013 04:01pm EDT 

Hologic Inc announced that it has completed its sale of the LIFECODES business unit to Immucor, Inc. Hologic has received $85 million in cash (adjusted for working capital items) with the opportunity to earn a contingent payment of $10 million based on the achievement of certain financial targets for the calendar year 2013. The closing follows the receipt of all necessary regulatory approvals.  Full Article

Hologic Inc Issues Q2 2013 Guidance Below Analysts' Estimates; Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Monday, 4 Feb 2013 04:01pm EST 

Hologic Inc announced that for the second quarter of 2013, it expects non-GAAP adjusted revenues of $635 million to $640 million (excludes an expected purchase accounting reduction of $5.2 million related to the Novartis collaboration). The increase is driven primarily by the inclusion of revenues related to the Gen-Probe acquisition, the continued ramp-up of new products including the Dimensions, PANTHER, and MyoSure systems and an expected overall improvement in each of the Company's operating segments, partially offset by an elimination in Adiana system revenues and revenues associated with LIFECODES which is expected to be sold during the quarter and expects non-GAAP adjusted EPS of $0.33 to $0.34. This reflects the expected benefit of approximately $0.01 from the recently-reinstated federal research tax credit, the expected impact of the medical device excise tax which is to be $0.02 dilutive. For fiscal 2013, the Company is reaffirming its non-GAAP adjusted revenues of $2.61 billion to $2.64 billion and expects non-GAAP adjusted EPS of $1.58 to $1.60. This is $0.02 higher than the guidance provided on November 12, 2012 due to the recently-reinstated federal research tax credit, partially offset by a slight increase in expected operating expenses. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $650 million and EPS of $0.38 for the second quarter of 2013; revenues of $2.63 billion and EPS of $1.58 for fiscal 2013.  Full Article

Hologic Inc Announces FDA Clearance of APTIMA Trichomonas for Use on PANTHER System
Monday, 14 Jan 2013 06:00am EST 

Hologic Inc announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System. The APTIMA Trichomonas vaginalis Assay, first cleared for use on Hologic's TIGRIS System in April 2011 , remains the only FDA-cleared amplified nucleic acid test on the market specifically cleared to detect Trichomonas vaginalis, the most common curable sexually transmitted infection in the United States. The assay may be used to test clinician-collected endocervical or vaginal swabs, and specimens collected in Hologic's ThinPrep vial from symptomatic or asymptomatic women.  Full Article

Search Stocks